Compensation award — excluded from discretionary-purchase analysis.
Traded Jan 15, 2026 · Filed Jan 16, 2026
Becton Dickinson's & Pres Med.Essntl&BioPharm sold $125K of Becton Dickinson shares. Nobody planned it ahead of time.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$125,400
Shares × reported transaction price
70 days after results of Nov 6, 2025, 25 days before results of Feb 9, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $208.35 on Jan 15, 2026, 26% above its 52-week low and 16% below its high, after a 9% rise over the previous 30 trading days
52-week range $165.15 (May 6, 2025) to $249.08 (Jan 28, 2025), 51% of the way up, from 251 adjusted closes. 30 trading days earlier: $190.47 on Dec 2, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | 0.0% | +2.6% | -2.6% |
| 30 days | -10.3% | +1.0% | -11.3% |
| 90 days | -22.0% | +4.6% | -26.6% |
| 180 days | -24.1% | +9.5% | -33.6% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.